ERIBULIN MONOMETHANESULFONATE
Toxicity
Oncologia Medica dell'Ospedale FatebenefratelliSmall moleculePhase 4 / ApprovedDormant
BB
68/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 53/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the Toxicity cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Irinotecan Institut Cancerologie de l'Ouest | Phase 2 | BB |
Eloxatin National Cancer Institute, Egypt | Phase 2 | B |
Carboplatin Instituto Nacional de Cancerologia de Mexico | Phase 2 | B |
Capecitabine National Cancer Institute, Egypt | Phase 2 | B |
FLUOROURACILUM Institut Cancerologie de l'Ouest | Phase 2 | B |
View all 10 →
Same molecule, other indications
ERIBULIN MONOMETHANESULFONATE is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →